INS and type 2 diabetes mellitus: Administration of STZ was found capable of developing peripheral insulin resistance or impairing insulin secretion from pancreatic β cells and it is sufficient to induce noninsulin-dependent diabetes mellitus (type 2) in animals (Qinna and Badwan, 2015).